Canaccord analyst Gary Nachman lowered the firm’s price target on Adma Biologics (ADMA) to $18 from $21 and keeps a Buy rating on the shares. The firm said 1Q26 was a reset quarter for the company with results that fell short and guidance lowered mainly due to pressure on Bivigam within the standard IG market. Importantly, key product and value driver Asceniv held up pretty well in 1Q.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ADMA:
- Adma Biologics options imply 12.3% move in share price post-earnings
- Adma Biologics reports Q1 EPS 19c, consensus 20c
- Adma Biologics sees FY26 revenue $530M-$560M, consensus $629.1M
- Analyst Reaffirms Buy Rating on ADMA Biologics, Citing Expanded Asceniv FDA Label and Strong Growth Outlook Despite Bivigam Concerns
- Adma Biologics announces FDA approval for Asceniv sBLA